Affiliation:
1. From the Population Studies and Prevention Program, Breast Cancer Program, and Developmental Therapeutics Program, Karmanos Cancer Institute; Departments of Internal Medicine, Biochemistry and Molecular Biology, Physiology, and Pathology, Wayne State University School of Medicine, Detroit, MI
Abstract
PurposeEstrogen receptor (ER) expression in lung tumors suggests that estrogens may play a role in the development of lung cancer. We evaluated the role of hormone-related factors in determining risk of non–small-cell lung cancer (NSCLC) in women. We also evaluated whether risk factors were differentially associated with cytoplasmic ER-α and/or nuclear ER-β expression–defined NSCLC in postmenopausal women.Patients and MethodsPopulation-based participants included women aged 18 to 74 years diagnosed with NSCLC in metropolitan Detroit between November 1, 2001 and October 31, 2005. Population-based controls were identified through random digit dialing, matched to patient cases on race and 5-year age group. Interview data were analyzed for 488 patient cases (241 with tumor ER results) and 498 controls.ResultsIncreased duration of hormone replacement therapy (HRT) use in quartiles was associated with decreased risk of NSCLC in postmenopausal women (odds ratio = 0.88; 95% CI, 0.78 to 1.00; P = .04), adjusting for age, race, pack-years, education, family history of lung cancer, current body mass index, years exposed to second-hand smoke in the workplace, and obstructive lung disease history. Among postmenopausal women, ever using HRT, increasing HRT duration of use in quartiles, and increasing quartiles of estrogen use were significant predictors of reduced risk of NSCLC characterized as ER-α and/or ER-β positive. None of the hormone-related variables were associated with nuclear ER-α–or ER-β–negative NSCLC.ConclusionThese findings suggest that postmenopausal hormone exposures are associated with reduced risk of ER-α–and ER-β–expressing NSCLC. Understanding tumor characteristics may direct development of targeted treatment for this disease.
Publisher
American Society of Clinical Oncology (ASCO)
Reference32 articles.
1. Differences in Lung Cancer Risk Between Men and Women: Examination of the Evidence
2. Ryberg D, Hewer A, Phillips DH, et al: Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients. Cancer Res 54:5801,1994-5803,
3. Mollerup S, Ryberg D, Hewer A, et al: Sex differences in lung CYP1A1 expression and DNA adduct levels among lung cancer patients. Cancer Res 59:3317,1999-3320,
4. p53mutations in lung tumours: relationship to gender and lung DNA adduct levels
5. Distinct Epidermal Growth Factor Receptor and KRAS Mutation Patterns in Non–Small Cell Lung Cancer Patients with Different Tobacco Exposure and Clinicopathologic Features
Cited by
126 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献